Thursday, December 07, 2017 4:10:20 PM
http://otce.finra.org/DLSymbolNameChanges
To bite the worm of incite is to bite the HOOK of the antagonist . They win .
Recent PCSA News
- Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:15:00 PM
- Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 03/25/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 01:15:00 PM
- Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference • GlobeNewswire Inc. • 02/14/2024 06:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:30:35 PM
- Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 11:32:03 PM
- Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering • GlobeNewswire Inc. • 02/01/2024 09:22:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 03:46:33 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/29/2024 09:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/29/2024 05:15:11 AM
- Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering • GlobeNewswire Inc. • 01/26/2024 02:04:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:35:27 PM
- Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 01:00:12 PM
- Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer • GlobeNewswire Inc. • 01/19/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:30:13 PM
- Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 01/18/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:30:19 PM
- Processa Pharmaceuticals to Present at the Biotech Showcase 2024 • GlobeNewswire Inc. • 01/02/2024 10:06:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 01:55:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 02:00:27 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM